Abstracts tagged "dermatomyositis"

Abstract Number: 1167 • ACR Convergence 2023
Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai³ and Moe Tokunaga(Sakamoto)³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
Abstract Number: 1949 • ACR Convergence 2023
Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis
Noriko Sasaki, Toshiki Ohisa, Akira Ishii, Mai Sugiyama, Yuichiro Ota, Chiho Yamada and Shinji Sato, Tokai university School of Medicine, Isehara, Japan
Background/Purpose: Autoantibodies to Melanoma Differentiation-Associated Gene 5 (MDA5) are found specifically in patients with dermatomyositis (DM). Their presence is closely associated with rapidly progressive interstitial…
Abstract Number: 0297 • ACR Convergence 2023
Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series
Eaman Alhassan¹, Belina Yi², Jack Rodman¹ and Leanna Wise³, ¹University of Southern California, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA, ³LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: There is little to no data about the presentation and clinical course of anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5) dermatomyositis patients in a primarily U.S.…
Abstract Number: 1175 • ACR Convergence 2023
Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Yusra Hasan¹, Katharine Ching Chung², Dana Ascherman³, Siamak Moghadam-Kia⁴, Chester V. Oddis³ and Rohit Aggarwal³, ¹CHI Health Creighton University Medical Center, Omaha, NE, ²University of Pittsburgh Medical Center, Mckeesport, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…
Abstract Number: 1951 • ACR Convergence 2023
Valid and Reliable Physical Function Tests in Idiopathic Inflammatory Myositis
Tanya Chandra¹, Raisa Lomanto Silva², shiri keret³, Akanksha Sharma⁴, Siamak Moghadam-Kia², Dana Ascherman⁵, Chester V. Oddis⁵ and Rohit Aggarwal⁵, ¹Georgetown University Hospital, Washington, DC, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Bnai Zion, Atlit, Israel, ⁴UPMC Mercy Hospital, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can cause significant impairment in physical function. Sit to Stand (STS) and Timed Up and Go (TUG) are quick and…
Abstract Number: 0300 • ACR Convergence 2023
Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls
Megan Sullivan¹, Maximiliano Diaz-Menindez², Colleen T. Ball², Benjamin Wang³ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic Jacksonville, Jacksonville, FL, ³Mayo Clinic, Jacksonville, FL
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a group of autoimmune disorders that cause inflammation of the muscle. This includes dermatomyositis and polymyositis. Literature has been…
Abstract Number: 1176 • ACR Convergence 2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Jiri Vencovsky¹, Jolie Feldman², Lisa McConnachie² and Brendan M. Johnson², ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…
Abstract Number: 1952 • ACR Convergence 2023
Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series
David Wang¹, Arezou Khosroshahi² and Prateek Gandiga², ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Atlanta, GA
Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung…
Abstract Number: 0301 • ACR Convergence 2023
Inflammatory Myopathies and Their Relationship with Cancer in a Colombian Cohort
Bolaños Juan D.¹, Rivera-Londoño Robert¹, Ivana Nieto-Aristizabal¹, Karol Enriquez², Santiago Zura², Alex Echeverri¹, Andrés Hormaza-Jaramillo¹ and David Aguirre-Valencia¹, ¹Fundación Valle del Lili, Cali, Colombia, ²Universidad ICESI, Cali, Colombia
Background/Purpose: Inflammatory myopathies (IM) constitute a heterogeneous group of autoimmune muscle diseases. These can occur in isolation, associated with other autoimmune disorders, or as a…
Abstract Number: 1180 • ACR Convergence 2023
Machine Learning Approach for the Prediction of anti-MDA5 Positive Dermatomyositis Mortality
Xinlei Liu¹, Fumin Qi², Wei Wei¹ and Yin Zhao¹, ¹Tianjin Medical University General Hospital, Tianjin, China, ²Tianjin Medical University, Tianjin, China
Background/Purpose: We describe a single-center clinical cohort of MDA5 positive dermatomyositis(DM) in China and apply a machine learning approach to predict the risk of mortality…
Abstract Number: 1954 • ACR Convergence 2023
Evaluation of Cancer Screening Methods in Patients Diagnosed with Inflammatory Muscle Disease at Kansas University Medical Center
Padmini Giri¹, Amrita Bath² and Pooja Bhadbhade², ¹University of Kansas Medical Center, Overland Park, KS, ²University of Kansas Medical Center, Kansas City, MO
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by muscle weakness and inflammation. There is an increased risk of developing cancer in patients (pts) with IIM…
Abstract Number: 0307 • ACR Convergence 2023
Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis
Jun Nakamura¹, Takao Nagashima² and Kojiro Sato², ¹Jichi Medical University, Shimotsuke, Japan, ²Jichi Medical University, Tochigi, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is frequently complicated by rapidly progressive interstitial lung disease (ILD) and is life-threatening especially in the…
Abstract Number: 1221 • ACR Convergence 2023
Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM)
Albert Chow¹, Sean Koester², Evan Pepper-Tunick³, Peggy Lee⁴, Mary Eckert⁵, Laurie Brenchley⁶, Pamela Gardner⁶, Naisi Li², adam Schiffenbauer⁷, Rita Volochayev⁷, Nastaran Bayat⁸, Jeffrey McLean⁹, Lisa Rider¹⁰, Susan Shenoi¹¹, Anne Stevens¹² and Neelendu Dey¹³, ¹Loma Linda University, Loma Linda, CA, ²Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, ³Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, ⁴Department of Oral Medicine, School of Dentistry, University of Washington, Seattle, WA, ⁵Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA, ⁶Office of the Clinical Director, NIDCR, National Institutes of Health, Bethesda, MD, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁸Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁹Department of Periodontics, University of Washington, Seattle, WA, ¹⁰NIEHS, NIH, Bethesda, MD, ¹¹Seattle Childrens Hospital, Mercer Island, WA, ¹²Janssen, Hansville, WA, ¹³Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA
Background/Purpose: JDM is a rare immune-mediated disease of childhood that is thought to result from genetic predisposition and environmental drivers, with documented links to microbial…
Abstract Number: 1960 • ACR Convergence 2023
From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence
Hao Cheng Shen¹, Victoria Ivensky², Yves Troyanov³, Josiane Bourre-Tessier¹, Farah Zarka², Sabrina Hoa⁴, Jessica Nehme², Jean-Paul Makhzoum⁵, Anne-Marie Mansour², Rosalie-Selene Meunier², Alexandra Mereniuk², Darosa Lim⁶, Jean-Pierre Raynauld¹, Eric Rich¹, Jean-Richard Goulet¹, Marianne Landry⁷, Maude Bouchard-Marmen⁸, Valerie Leclair⁹, Hugues Allard-Chamard¹⁰, Marie Hudson¹¹, Erin O'Ferrall¹², Rami Massie¹², Jason Karamchandani¹³, Benjamin Ellezam¹⁴, Ira N. Targoff¹⁵, Minoru Satoh¹⁶, Marvin Fritzler¹⁷, Jean-Luc Senecal¹, Alain Meyer¹⁸ and Oceane Landon-Cardinal¹, ¹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, QC, Canada, ³Hôpital du Sacré-Coeur de Montréal, Centre hospitalier de l'Université de Montreal (CHUM), Université de Montréal, Montreal, QC, Canada, ⁴University of Montreal, Brossard, QC, Canada, ⁵Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Hôpital de LaSalle, Montreal, QC, Canada, ⁸CHU de Québec, Université Laval, Quebec City, QC, Canada, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Université de Sherbrooke, Sherbrooke, QC, Canada, ¹¹McGill University, Montréal, QC, Canada, ¹²Montreal Neurological Institute, McGill University, Montreal, QC, Canada, ¹³McGill University Health Center (MUHC), McGill University, Montreal, QC, Canada, ¹⁴CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada, ¹⁵Veteran's Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁷University of Calgary, Calgary, AB, Canada, ¹⁸Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: The risk of cancer is increased in patients with pure dermatomyositis (DM), i.e. patients with a DM rash and without an anti-MDA-5 syndrome, a…
Abstract Number: 0337 • ACR Convergence 2023
Impact of Photosensitivity on Quality of Life in Dermatomyositis
Kirubel Gebre¹, Rachita Pandya², Julianne Kleitsch², Darosa Lim³, Rui Feng³ and victoria werth⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Lancaster, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Wynnewood, PA
Background/Purpose: Photosensitivity (PS) has been documented in dermatomyositis (DM) with symptoms including aggravation of preexisting cutaneous lesions and abnormal transient erythemal responses (Cheong WK et…

« Previous Page
1
…
5
6
7
8
9
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].